StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO)

Investment analysts at StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a note issued to investors on Thursday. The brokerage set a “hold” rating on the medical research company’s stock.

Separately, D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Cytosorbents presently has an average rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Stock Performance

Shares of CTSO stock opened at $0.97 on Thursday. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $1.61. The business has a 50 day simple moving average of $1.07 and a 200 day simple moving average of $1.04. The firm has a market capitalization of $53.04 million, a price-to-earnings ratio of -2.69 and a beta of 0.78.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Monday, March 31st. The medical research company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.04. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. The business had revenue of $9.20 million during the quarter, compared to the consensus estimate of $10.09 million. On average, equities research analysts anticipate that Cytosorbents will post -0.3 EPS for the current year.

Institutional Investors Weigh In On Cytosorbents

A number of institutional investors and hedge funds have recently bought and sold shares of CTSO. Renaissance Technologies LLC grew its stake in shares of Cytosorbents by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after purchasing an additional 8,400 shares during the last quarter. Northern Trust Corp boosted its holdings in Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after buying an additional 16,701 shares in the last quarter. Skylands Capital LLC grew its position in Cytosorbents by 1.0% in the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock worth $2,531,000 after buying an additional 26,195 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after acquiring an additional 32,415 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in shares of Cytosorbents during the 4th quarter worth $30,000. 32.87% of the stock is owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.